Presentation (CTI)

OBJECTIVES: To examine how the European Union’s Joint Clinical Assessment (JCA) process—and the ongoing uncertainties surrounding its implementation—may influence market access strategies in the United States (US) despite lacking formal jurisdiction over US regulatory or payer decision-making.
METHODS: A focused review of peer-reviewed literature, policy analyses, industry white papers, and grey literature from regulatory, health technology assessment, and stakeholder websites identified key sources on JCA implementation, evidence requirements, global strategies, and US payer dynamics. Findings were synthesized to identify mechanisms linking JCA-driven changes in evidence generation to potential US impacts.
RESULTS: The JCA has no direct impact on US market access processes, but it may exert indirect influences through several mechanisms. First, JCA-driven methodological requirements—particularly comparative-effectiveness evidence, and comparator justification —are beginning to shape global clinical-development programs, potentially affecting US market-access dossiers and payer communications as companies adopt unified global evidence packages. Second, ongoing uncertainties in the JCA process—such as evolving comparator expectations, evidence standards, and timeline variability— increase challenges for US market access by influencing trial design, real-world evidence generation, and launch sequencing. Finally, US payers may monitor JCA outcomes, meaning ambiguous or delayed JCA outputs could impact formulary decisions, coverage restrictions, and negotiation leverage.
CONCLUSIONS: While the JCA does not directly affect US market access, its implementation and associated uncertainties are already reshaping global evidence generation in ways that may impact US payer engagement, value messaging and launch strategy.